BioCentury
ARTICLE | Company News

NovaDigm, Harbor-UCLA Medical Center deal

June 30, 2014 7:00 AM UTC

NovaDigm acquired exclusive, worldwide rights to Candida albicans hyphally regulated cell wall protein 1 ( Hyr1), a Candida vaccine antigen, from Harbor-UCLA Medical Center’s Los Angeles BioMedical R...